Marker Therapeutics treats first patient in Phase 1 OTS MAR-T cell study; well tolerated

Marker Therapeutics, Inc.

First patient dosed at 100x10^6 cells in Phase 1 RAPID study evaluating MT-401 as Off-the-Shelf product.
No treatment-related adverse events observed in first patient; safety consistent with prior MAR-T cell data.
OTS product aims to accelerate time to treatment to as fast as 72 hours using healthy donor material.
Non-dilutive funding from FDA, NIH SBIR, and CPRIT supports OTS program without affecting cash runway.
APOLLO study in lymphoma reported 66% objective response rate and durable complete responses.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.